The Food and Drug Administration will give priority review to a first-of-its-kind maternal vaccine against respiratory syncytial virus via the breakthrough therapy program.

It’s been called the “tripledemic” – the flu, COVID-19 and RSV colliding in a dangerous viral storm. And now new data suggest that RSV, or respiratory syncytial virus, may pose an even greater burden than some realized. 

After my infant son had open-heart surgery, I thought we’d been through the worst experience of our lives. Then he got RSV.